Recruiting
PHASE4
INTERVENTIONAL
NCT06605703
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
Interventions
Name:
WW Clinic
Type:
BEHAVIORAL
Description:
Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
Name:
Bupropion-Naltrexone
Type:
DRUG
Description:
Bupropion-Naltrexone
Name:
Bupropion-Naltrexone-Metformin
Type:
DRUG
Description:
Bupropion-Naltrexone-Metformin
Primary Outcomes
Measure:
Percent body weight change at 12 weeks
TimeFrame:
Baseline, 12 weeks
Description:
Measurement of weight using a bluetooth body weight scale
Trial Information
NCT ID
NCT06605703
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Michelle Cardel, PhD, MS, RD
Last Updated
December 15, 2025